2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reductionAsthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024, 133: 302-309. PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burdenImpact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study
Liu M, Chaudhuri R, Chupp G, Heaney L, Lee J, Pilette C, Brusselle G, Alfonso Cristancho R, Zhang L, Howarth P. Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study. 2024, a5376-a5376. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5376.Peer-Reviewed Original Research
2023
Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years
Brusselle G, Lougheed M, Canonica G, Munoz-Esquerre M, Heaney L, Price R, Howarth P, Raimondi A, Gardiner F, Chupp G, Welte T. Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years. 2023, a5985-a5985. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5985.Peer-Reviewed Original ResearchRemission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals
2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
Corren J, Wechsler M, Chupp G, Roseti S, Hellqvist Å, Martin N, Llanos J, Ambrose C, Colice G. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 943-945.e2. PMID: 36375743, DOI: 10.1016/j.jaip.2022.10.042.Peer-Reviewed Original ResearchMepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma
Chupp G, Lee J, Liu M, Schleich F, Heaney L, Ribas C, Carrillo-Díaz T, Aparicio M, Moragón E, Sanchez-Herrero M, Gardiner F, Alfonso-Cristancho R, Jakes R, Price R, Howarth P. Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma. Journal Of Allergy And Clinical Immunology 2022, 149: ab318. DOI: 10.1016/j.jaci.2021.12.019.Peer-Reviewed Original Research
2021
Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years
Bourdin A, Korn S, Chupp G, Cosio B, Arbetter D, Shah M, Garcia Gil E. Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years. 2021, a1205-a1205. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1205.Peer-Reviewed Original Research
2019
Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty
Mohan A, Grace J, Mainardi A, Chupp G, Lugogo N. Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty. Respiratory Medicine 2019, 123-153. DOI: 10.1007/978-3-030-20812-7_8.Peer-Reviewed Original ResearchSevere asthmaBronchial thermoplastyBiologic therapySurrogate markerOral corticosteroid exposureHeterogeneous inflammatory diseaseIdentification of respondersMultiple pathologic mechanismsAsthma controlCorticosteroid exposureDisease activityAsthma symptomsAsthma therapyPredictive markerInflammatory diseasesPrognostic markerTargeted therapyCurrent biomarkersPathologic mechanismsAsthmaDrug AdministrationParticular patientPatientsTherapyAdvanced therapies
2009
Intensive Care Unit Management of Status Asthmaticus
Marshall P, Possick J, Chupp G. Intensive Care Unit Management of Status Asthmaticus. Clinical Pulmonary Medicine 2009, 16: 293-301. DOI: 10.1097/cpm.0b013e3181bdff38.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSevere asthma exacerbationsNear-fatal asthmaStatus asthmaticusMechanical ventilationAsthma exacerbationsExtrinsic positive end-expiratory pressureIntensive care unit managementPositive end-expiratory pressureEmergency department visitsNoninvasive mechanical ventilationSubset of patientsEnd-expiratory pressureTypical risk factorsHigh-risk populationRisk of barotraumaUse of sedativesSevere exacerbationsICU admissionSevere asthmaPermissive hypercapniaSystemic therapyDepartment visitsHospital admissionExpiratory pressureRisk stratification
2007
A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma. New England Journal Of Medicine 2007, 357: 2016-2027. PMID: 18003958, DOI: 10.1056/nejmoa073600.Peer-Reviewed Original ResearchConceptsSerum YKL-40 levelsYKL-40 levelsSeverity of asthmaYKL-40Chitinase-like proteinsParis cohortOral corticosteroid useCohort of patientsRescue inhaler useSubgroup of patientsCirculation of patientsCorticosteroid useSevere asthmaAirway remodelingClinical characteristicsExpiratory volumeAcidic mammalian chitinasePatient populationHigh serumAsthmaImmunohistochemical analysisPatientsAnimal modelsLocus of expressionMorphometric quantitation